Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulations PRINCETON, N.J.— 2023年8月29日– Certara (Nasdaq: CERT), a global leader in biosimulation, today announced that the Simcyp group has been awarded two new grants from the U.S. Food and Drug Administration (FDA) to expand its … Continued
Provides Update to Full Year 2023 Financial Guidance PRINCETON, N.J.— August 9, 2023– Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, today reported its financial results for the second quarter of fiscal year 2023. Second Quarter Highlights: “During the second quarter our software business performed well, but we experienced lower growth than expected in our … Continued
PRINCETON, N.J.— 2023年7月13日– Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2023 after the market close on Wednesday, August 9th, 2023. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening … Continued
2023年6月2日ニュージャージー州プリンストン - バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, today announced that Company management will participate in the Jefferies Global Healthcare Conference. Company management will present at 1:30PM ET on Wednesday, June 7th, 2023. A live webcast of the event will be available on Certara’s investor relations website at … Continued
Reiterates 2023 Financial Guidance PRINCETON, N.J.— 2023年5月8日– Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2023. First Quarter Highlights: “We are pleased with our first quarter financial results and performance in software and biosimulation services” said William F. Feehery, chief … Continued
Asserts Certara’s leadership in advancing the development and approval of new drugs for patients PRINCETON, N.J.— 2023年4月27日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, today announced that 90 percent of new drug approvals by the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Review (CDER) were received … Continued
PRINCETON, N.J.— 2023年4月10日– Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2023 after the market close on Monday, May 8th, 2023. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening … Continued
新しいディープラーニング機能により、物性の優先順位付け、新規構造の設計、文献に基づく分析に役立つ情報を提供： ニュージャージー州プリンストン、3月 9日 — サターラ：バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) は科学情報学をリードするソフトウェアプラットフォームのD360に、ディープラーニング機能を追加すると発表しました。つづく...
Simcyp Simulator has been utilized to inform more than 300 label claims for 90+ novel drugs in lieu of conducting clinical studies PRINCETON, N.J.— 2023年3月7日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, today announced the release of Simcyp Simulator Version 22, which includes new capabilities and updated features to the Company’s population-based … Continued
Annual Revenue Grows 17% on a Reported Basis and 20% at Constant Currency PRINCETON, N.J.— 2023年3月1日– Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, today reported its financial results for the fourth quarter and full year of 2022 and issued guidance for 2023. Fourth Quarter Highlights: Full Year Highlights: “We are pleased … Continued
